Arwan Pharmaceutical Industries, Lebanon

arwanlb.com

Arwan Pharmaceutical Industries,are one of the most advanced biotech manufacturing facilities in the MENA and Africa. Our ultimate goal is to secure quality critical care medicine to all patients who need them. Thus, quality is embedded in each and every step of our operations, from the buildings, machineries, materials, methods and manpower. Empowered by our passion for achievement, strong belief in our capabilities, and the emphasis on performance with integrity, we continue to work according to our motto:

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PROTEONIC ANNOUNCES LICENSING OF TECHNOLOGY FOR BOOSTING THERAPEUTIC PROTEIN PRODUCTION TO IMMUNOMEDICS

ProteoNic | October 20, 2020

news image

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of speci...

Read More

Cell and Gene Therapy

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

news image

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More

Industrial Impact

SECOND GENOME ANNOUNCES BAYER EXERCISED OPTION FOLLOWING COMPLETION OF MULTI-YEAR COLLABORATION

Second Genome | March 03, 2022

news image

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. During the collaboration, Second Genome generated and explored environmental metagenomes that include genomic information from bacteria that are yet to be identified and cultured. Read More

AMUNIX RAISES $73 MILLION IN SERIES A FINANCING LED BY OMEGA FUNDS

BioSpace | March 04, 2020

news image

Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, C...

Read More
news image

PROTEONIC ANNOUNCES LICENSING OF TECHNOLOGY FOR BOOSTING THERAPEUTIC PROTEIN PRODUCTION TO IMMUNOMEDICS

ProteoNic | October 20, 2020

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of speci...

Read More
news image

Cell and Gene Therapy

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More
news image

Industrial Impact

SECOND GENOME ANNOUNCES BAYER EXERCISED OPTION FOLLOWING COMPLETION OF MULTI-YEAR COLLABORATION

Second Genome | March 03, 2022

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. During the collaboration, Second Genome generated and explored environmental metagenomes that include genomic information from bacteria that are yet to be identified and cultured. Read More

news image

AMUNIX RAISES $73 MILLION IN SERIES A FINANCING LED BY OMEGA FUNDS

BioSpace | March 04, 2020

Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, C...

Read More